Journals / Acıbadem Üniversitesi Sağlık Bilimleri Dergisi / 2020 / Sayı: 4

Hypophysitis

Hipofizit

Pages
561–566
Publication Date
2020-12-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this evaluation, in the light of most up-to-date literature information, classification of hypophysitis, its clinical importance and treatment approaches are discussed

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Hypophysitis is an autoimmune heterogeneous inflammatory disease of the pituitary gland.
📊
Key Findings & Data:It is seen in two forms being primary and secondary.
💡
Conclusion & Impact:In this evaluation, in the light of most up-to-date literature information, classification of hypophysitis, its clinical importance and treatment approaches are discussed
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Hypophysitis · lymphocytic hypophysitis

Abstract

Hypophysitis is an autoimmune heterogeneous inflammatory disease of the pituitary gland. It is seen in two forms being primary and secondary. Lymphocytic hypophysitis is the most commonly observed form of hypophysitis and it is a disease capable of disrupting the hormonal secretions of the pituitary gland, imitating pituitary adenomas, and sometimes even causes mortality due to pituitary failure. The purpose of the treatment is to reduce the existing symptoms, to minimize the hypophyseal tumor and to eliminate the resultant hormonal deficiencies. The most commonly used medications in medical treatment are the glucocorticoids and they ensure minimization of the pituitary gland and improve pituitary function. In cases of glucocorticoids inadequacy, the other immunosuppressive medications, such as azathioprine, methotrexate and cyclosporine A, might be used. Surgical treatment might be necessary in some cases. In this evaluation, in the light of most up-to-date literature information, classification of hypophysitis, its clinical importance and treatment approaches are discussed

Özet

Hipofizit, hipofiz bezinin otoimmun heterojen inflamatuar bir hastalığıdır. Primer ve sekonder olmak üzere 2 formda görülür. Lenfositik hipofizit en sık görülen hipofizit formudur ve hipofizin hormonal sekresyonlarını bozabilen, hipofiz adenomlarını taklit edebilen ve bazen hipofiz yetersizliği ile mortaliteye neden olabilen bir hastalıktır. Tedavide amaç var olan semptomların azaltılması, hipofizer kitlenin küçültülmesi ve meydana gelen hormonal eksikliklerin giderilmesidir. Medikal tedavide en sık kullanılan ilaçlar glukokortikoidlerdir ve hipofiz bezinin küçülmesini ve hipofiz fonksiyonlarının düzelmesini sağlarlar. Glukokortikoidlerin yetersiz kaldığı olgularda azotiopurin, methotrexate, cyclosporin A gibi diğer immusupresif ilaçlar kullanılabilir. Cerrahi tedavi bazı olgularda gerekli olabilir. Bu değerlendirmede, güncel literatür bilgileri ışığında hipofizitin sınıflaması, klinik önemi ve tedavi yaklaşımları tartışılmıştır

🔖

Cite This Article

KARA, M. (2020). Hypophysitis. Acıbadem Üniversitesi Sağlık Bilimleri Dergisi, Sayı: 4, 561–566. https://ajindex.com/articles/162732

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Caturegli P, Newschaffer C, Olivi A, Pomper MG, Burger PC, Rose NR. Autoimmune Hypophysitis. Endocr Rev 2005;26:599–614. [CrossRef] Lupi I, Manetti L, Raffaelli V, Lombardi M, Cosottini M, Iannelli A, et al. Diagnosis and Treatment of Autoimmune Hypophysitis: A Short Review. J Endocrinol Invest 2011;34:e245–52. [CrossRef] Goudi EB, Pinkerton PH. Anterior Hypophysitis and Hashimoto’s Disease in a Young Woman. J Pathol Bacteriol 1962;83:584–85. [CrossRef] Honegger J, Schlaffer S, Menzel C, Droste M, Werner S, Elbelt U, et al. Diagnosis of Primary Hypophysitis in Germany. J Clin Endocrinol Metab 2015;100:3841–9. [CrossRef] Betterle C, Greggio NA, Volpato M. Clinical Review 93: Autoimmune Polyglandular Syndrome Type 1. J Clin Endocrinol Metab 1998;83:1049–55. [CrossRef] Heaney AP, Sumerel B, Rajalingam R, Bergsneider M, Yong WH, Liau LM. HLA Markers DQ8 and DR53 are Associated with Lymphocytic Hypophysitis and May Aid in Differential Diagnosis. J Clin Endocrinol Metab 2015;100:4092–7. [CrossRef] Yaoita R, Ito M, Matsuda K, Kokubo Y, Sato S, Sonoda Y. A Case of Lymphocytic Adenohypophysitis Presenting Visual Disturbance in the Third Trimester of Pregnancy. No Shinkei Geka. 2017;45:161-5. [CrossRef] Lammert A, Schneider HJ, Bergmann T, Benck U, Kramer BK, Gärtner R, et al. Hypophysitis Caused by Ipilimumab in Cancer Patients: Hormone Replacement or Immunosuppressive Therapy. Exp Clin Endocrinol Diabetes 2013;121:581–7. [CrossRef] Faje A. Immunotherapy and Hypophysitis: Clinical Presentation, Treatment, and Biologic Insights. Pituitary 2016;19:82–92. [CrossRef] Tebben PJ, Atkinson JL, Scheithauer BW, Erickson D. Granulomatous Adenohypophysitis After Interferon and Ribavirin Therapy. Endocr Pract 2007;13:169–75. [CrossRef] Gutenberg A, Caturegli P, Metz I, Martinez R, Mohr A, Brück W, Rohde V. Necrotizing Infundibulo-Hypophysitis: an Entity too Rare to be True? Pituitary 2012;15:202–8. [CrossRef] De Lange TE, Simsek S, Kramer MH, Nanayakkara PW. A Case of Cocaine-Induced Panhypopituitarism with Human Neutrophil Elastase-Specific Anti-Neutrophil Cytoplasmic Antibodies. Eur J Endocrinol 2009;160:499–502. [CrossRef] Hori M, Makita N, Andoh T, Takiyama H, Yajima Y, Sakatani T, et al. Long-term Clinical Course of IgG4-Related Systemic Disease Accompanied by Hypophysitis. Endocr J 2010;57:485–92. [CrossRef] Asa SL. Tumors of the Pituitary Gland. Atlas of tumor pathology. 3rd series, Fascicle 22. Washington DC: Armed Forces Institute of Pathology; 1998. pp.191–210. Catur